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plore their potential for translation into therapeutics to prevent disease promoting epigenome reprogramming
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Epigenetics is the study of how the genome is interpreted by the cell
to generate a phenotype. If taken literally this could include all of the
events involved in the regulation of gene expression. However for the
purpose of this review discussion will be limited to those regulatory
mechanisms that operate at the level of DNA methylation, histoneon "Fibroblasts
ancer".
edical Sciences,
lace, Newcastle
n access article undermodifications and the activities on non-coding regulatory RNA mole-
cules. But in addition, readers should be aware of the critical role that
transcription factors play in determining gene expression and cell phe-
notype. Transcription factors, which operate by recognising specific
DNA motifs in the promoter/enhancer regions of genes and then mod-
ulate the activity of RNA polymerase II, are increasingly featuring as im-
portant drug targets in chronic liver disease. Typical examples being the
peroxisome proliferator-activated receptors and the farnesoid X recep-
tor for which ongoing clinical trials are determining efficacy in non-al-
coholic fatty liver disease (NAFLD) and autoimmune liver disease [1–3].
DNA methylation is a direct chemical modification of DNA in which
methyl groups are predominantly added to cytosine residueswithin the
context of a CpG dinucleotide [4]. This modification is carried out by
three highly conserved enzymes, DNA methyltransferase 1 (DNMT1),the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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DNMT3A and DNMT3B enzymes that function as de novomethyltrans-
ferases, establishing methylation patterns during development [5]. As
a general rule the 5me-CpG mark is associated with gene repression
and in particular when it is associated with CpG-rich promoter regions
[6]. Hence, high density CpG promoters that are typical of housekeeping
genes are rarely methylated, while genes that have intermediate densi-
ty CpG content are silenced uponmethylation [7,8]. In contrast lowden-
sity CpG rich promoters remain transcriptionally active even when
hypermethylated. However, this perhaps over simplistic rule breaks
down in other regions of the genome, in particular within gene bodies
where DNA methylation can be associated with active transcription
[9]. Discovery of the three ten eleven translocation (TET1-3) enzymes,
which catalyse progressive oxidation of the 5-meCpG mark, implies
that DNA methylation is more dynamic than previously thought [10].
Disturbance in the balance of DNMT and TET activities has potential to
contribute to disease progression as evidenced by mutations in
DNMT3A and TET2 being frequently found in human cancers [11].
DNA is packaged into chromatin of which the unit structure is the
nucleosome which is comprised of two copies each of histones H2A,
H2B, H3 and H4 that assemble into an octamer around which 146–
147 bp of DNA is tightly wrapped. The nucleosome is a highly dynamic
structure and dictates the degree to which DNA is accessible for tran-
scription; this being determined by its degree of compaction and by
post-translational modifications (PTMs) on the N-terminal tails of its
constituent histones [12]. The core histone tails can bemodified by acet-
ylation, methylation, ubiquitination, sumoylation and phosphorylation
which combine to regulate chromatin structure and gene expression.
Lysine acetylation and methylation are the best characterised histone
PTMs, with the former being associated with transcriptionally active
genes while lysine methylation has a more modulatory function with
its influence determined by the location of the lysine residue on the his-
tone tail and the extent of its methylation (mono, di or trimethylation).
Acetylation is regulated by histone acetyltransferases (HATs) and his-
tone deacetylases (HDACs). HDACs are targets for an expanding cata-
logue of drugs many of which are in clinical studies in human cancers
where dysregulation of histone acetylation is mechanistically implicat-
ed in dysregulation of gene expression [13]. Histone lysinemethyltrans-
ferases (HMTs) and demethylases (KDMs) are also implicated in human
disease and are consequently subject to intense drug discovery [14].
Histone PTMs function as recognition signals for so-called histonemod-
ification readers, these being nuclear proteins that transmit the struc-
tural information in the chromatin to the transcriptional machinery.
Bromodomain-containing proteins or BETs (e.g. BRD2, BRD3, BRD4,
BRDT, ASH1L) are a particularly important class of histone readers that
recognise acetylated lysine residues and are key players in cancer and
inflammation [15]. Small molecule BET inhibitors have shown great
pre-clinical promise and are now in a variety of clinical studies [16].
The vastmajority of the human genome is transcribed, however only
2% encodes proteins. The vast majority of the transcriptome consists of
non-coding RNAs (ncRNAs) that have regulatory functions and include
micro RNAs (miRNA), small nucleolar RNAs (snoRNAs), small interfer-
ing RNAs (siRNAs), Piwi-interacting RNAs (piRNAs) and the long non-
coding RNAs (lncRNAs). The miRNAs are an extensively studied class
of single-stranded 18–22 nucleotide ncRNAs that fine-tune expression
of the genome either by decreasing the stability or suppressing transla-
tion ofmessenger RNAs [17]. The physiological importance ofmiRNAs is
demonstrated by the evidence for genetic and epigenetic alterations in
miRNA biogenesis being associated with oncogenesis [18]. Moreover,
miRNAs can be specifically targeted by chemically modified antisense
oligonucleotides which raises potential for their therapeutic manipula-
tion [19]. Recently lncRNAs, a large and diverse class of transcribed
RNA molecules with a length of N200 nucleotides that do not encode
proteins, have attracted considerable attention because of their myriad
of functions including control of chromatin remodelling, gene transcrip-
tion, protein transport and metabolism [20,21]. Mutations anddysregulated expression of lncRNAs are associated with a variety of dis-
eases including diabetes and cancer, raising potential for their applica-
tion as biomarkers for disease onset and progression [22].
Here we will consider recent advances in the role of DNA methyla-
tion, histone modifications and ncRNAs in chronic liver diseases and in
particular how new knowledge of these epigenetic mechanisms may
be exploited for improving the management of the two major liver dis-
ease endpoints, fibrosis/cirrhosis and cancer.2. Environmental impacts on the hepatic epigenetic landscape
The liver must adapt on a daily basis to a constant flux of environ-
mental variations including circadian oscillators, nutritional/metabolic
fluxes, exposure to xenobiotics, viral infections, alterations in the
microbiome and the demands for epithelial repair and regeneration.
Using a deep sequencing approach, Vollmers and colleagues systemati-
cally mapped the epigenetic changes occurring over 24 h in the mouse
liver [23]. Temporal changes were observed in 1262 transcripts of
which 464 were identified as protein coding, 19 as lncRNAs and 53 as
miRNAs including Let-7,miR-33,miR-103 andmiR-122 that have previ-
ously been associated with functional roles in liver physiology and dis-
eases [24–27]. Integrated with these transcriptional changes were
genome-wide oscillations in histone lysine modifications including for
the mark of transcriptional active chromatin H3K4me3, found at 826
gene promoters. Noteworthywas the absence of changes in DNAmeth-
ylation indicating the stability of this epigenetic mark in the normal
healthy liver. By contrast profound changes in DNA methylation occur
in the livers of mice fed a lipogenic diet that induces steatosis, an effect
associated with altered expression of DNMT1 and DNMT3A [28]. In
humans, obesity has been associated with accelerated liver ageing
based on analysis of the DNA methylome [29] and in human Nonalco-
holic steatohepatitis (NASH) increased DNMT1 is reported [30].
HDAC3 is an important circadian regulated epigenetic writer critical
for hepatic triglyceride homoeostasis and when deleted in mice results
in steatosis, inflammation and fibrosis [31,32]. Similarly the HDAC,
SIRT1 prevents NAFLD by regulating adipogenesis and suppressing NF-
κB-driven inflammation [33]. Around 100 miRNAs are dysregulated in
human NASH including the circadian regulated miR-122 which is
under-expressed in NASH [34]. Alcohol depletes S-adenosylmethionine
(SAMe), the major methyl donor for DNA and histone methylation, al-
ters the expression of multiple miRNAs and via its induction of hepatic
reactive oxygen species (ROS) promotes H3K9 acetylation leading to in-
creased expression of alcohol-metabolising enzymes that induce further
ROS and acetylation potentially establishing feed-forward epigenetic
re-landscaping [35].
Hepatitis C virus (HCV) infection promotesmultiple changes in DNA
methylation including at enhancer elements associatedwith altered ex-
pression of genes implicated in cancer and control of stem cells [36]. The
hepatitis B virus X protein (HBx) also alters DNA methylation via its
ability to influence DNMT activity and in addition recruits the histone
acetyltransferases p300/CBP to induce IL-8 and proliferating cell nuclear
antigen (PCNA) which are involved in inflammation and cell prolifera-
tion respectively [37]. Recent work by Thaiss et al. has shown that the
gutmicrobiota exhibits a diurnal rhythmicity that programs in a circadi-
anmanner the liver transcriptome and its detoxification pattern [38]. As
the gut microbiota is dramatically modified in alcoholic and non-alco-
holic liver diseases this new discovery has major implications for epige-
netic control of oscillatory hepatic gene expression and liver function
[39,40].
Hence, in summary the epigenetic landscape of the liver is acutely
sensitive to environmental cues resulting in modifications that impact
on its circadian controlled patterns of gene expression. In obesity and al-
coholic disease the disturbance to the hepatic epigenetic landscapemay
promote microenvironments in which steatosis advances to inflamma-
tion, fibrosis and cancer.
••
•
•
•
•
•
•
•
Fig. 1.The Implications of EZH2 as a therapeutic target infibrosis andHCC. The schematic outlines some of theways inwhich EZH2 is able to support growth, survival andmigration of liver
cancer and activation of the scar forming myofibroblasts of the liver.
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Myofibroblasts are the major cellular drivers of liver fibrosis and ap-
pear during conditions of liver damage and/or infectionmainly through
the process of hepatic stellate cell (HSC) transdifferentiation. The con-
version of quiescent HSC to their activated myofibroblast state involves
vast changes in transcriptome expression that dramatically alter the
phenotype and behaviour of the cell. In the past decade we have
begun to shed light on the epigenetic events that reprogram the HSC
transcriptome, thus revealing new regulators of fibrogenesis as well as
potential biomarkers for tracking disease progression.
3.1. DNA methylation
Many of the regulatory events associated with in-vivo
transdifferentiation of HSC can be recapitulated in a cell culture model
in which isolated HSC are maintained for several days on plastic in
serum-containing media. In this widely used model, HSC
transdifferentiation was accompanied by a N20% methylation change
(hypo- or hyper-methylation) in ~400 methylated regions including
DNMT3A and DNMT3B [41]. These changes in methylationwere associ-
ated with either transcriptional repression or activation. For example,
peroxisome proliferator-activated receptor γ (PPARγ) gene silencing
is required for HSC activation [42] and this process is regulated by two
concurrent methylation-based epigenetic control mechanisms. Firstly,
the DNAmethylation readerMeCP2 is recruited tomethyl-CpGs located
in the promotor region of PPARγ and subsequently directs repressive
H3K9me3-modifying enzymes to suppress initiation of transcription.
Secondly, transcriptional elongation is suppressed by EZH2-mediated
H3K27me3 modifications in the downstream coding region of PPARγ,
with expression of EZH2beingdependent onMeCP2 [43] (Fig. 1). Signif-
icantly, HSC isolated from mice deficient in MeCP2 show attenuated
levels of classical myofibroblasts markers such as α-smooth muscle
actin (αSMA) or collagen 1 and are protected from carbon tetrachloride
(CCl4) induced liver fibrosis [43]. Conversely, MeCP2 has also been
shown to stimulate the transcription of multiple pro-fibrotic genes
through the control of ASH1, anH3K4/H3K36histonemethyltransferase
that directly binds to the regulatory regions ofαSMA, collagen 1, TIMP1
and TGF-β1 in activated HSCs, promoting their transcription [44].
Jumonji Domain-Containing Protein 1A (JMJD1A), an H3K9
demethylase involved in adipogenic metabolism, was also found toregulate PPARγ gene expression. Specifically, knockdown of JMJD1A in
HSC correlated with reinforced H3K9me2 in the PPARγ gene promoter,
increased αSMA and collagen expression, and enhanced necrosis in the
CCl4 mouse fibrosis model [45]. Taken together the data suggests that
MeCP2 and JMJD1A are critical epigenetic regulators of HSC phenotype
and fibrogenesis.
DNAmethylation in the PPARγ gene promotor has also been shown
to be relevant in human disease. In awell phenotyped cohort of patients
with biopsy proven NAFLD Zeybel et al. demonstrated that hyperme-
thylation at discreet CpG dinucleotides within the human PPARγ gene
promotor could be used to stratify patients with mild fibrosis (Kleiner
score 0–2) from those with severe fibrosis (Kleiner score 3–4) [46,47].
In a similar study in a cohort of Hepatitis B virus (HBV) infected patients,
disease progression correlated with DNA methylation changes at CpG
dinucleotides in the HoxA2, PPP1R18 and HDAC4 genes [47]. However,
measurements of DNA methylation in these studies relied on access to
liver biopsy tissue. More recently this limitation was overcome by
using pyrosequencing to quantify differential DNA methylation at the
PPARγ promoter from circulating cell-free DNA extracted from patient
plasma. Again this methodwas able to stratify betweenmild and severe
fibrosis in NAFLD [48]. If validated, this exciting approach could be
utilised as a potential plasma biomarker of liver fibrosis progression
that negates the need for biopsy. Furthermore, this study proposed
that the source of circulating cell-freeDNA is likely to be dying/damaged
hepatocytes, this interestingfinding suggests that fibrosis progression is
accompanied (or driven) by reprogramming of the hepatocyte DNA
methylome.
As previously explained DNA methylation is a dynamic epigenetic
marker that is regulated by DNMT and TET enzymes that stimulate
CpG methylation and demethylation respectively [49]. The importance
of TET proteins and DNMTs in liver fibrosis was confirmed using a
range of in vivo models of chronic liver disease (bile duct ligation
(BDL), CCl4 and methionine-choline deficient (MCD) diet) [50]. Experi-
mental liver fibrosis was accompanied by an induction of the de novo
methyltransferases DNMT3A/B expression, diminution of TET protein
expression and remodeling of the HSC DNAmethylome. Moreover, cul-
ture activated HSC and ex-vivo purified HSC from CCl4 injured rats also
demonstrated increased DNMT3A and DNMT3B, with knock-down of
the latter enzymes resulting in reduced fibrogenic features. Of note,
similar fibrosis-associated epigenetic changes were observed inmecha-
nistically distinct examples of chronic human liver disease supporting
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between the DNMTs and TETs [51]. There is potential to target DNA
methylation and this has been achieved in human cancers with 5-
azadeoxycytidine (5-AzadC), a DNMT inhibitor [52,53]. 5-AzadC is
able to suppress HSC transdifferentiation providing further evidence of
the importance of the DNA methylome in fibrosis [54]. However,
given the likely need to treat chronic liver disease patients with anti-fi-
brotics for their lifetime it is difficult at present to envisage therapeutic
manipulation of DNA methylation as a rationale strategy.
3.2. Histone modifications
Histone acetylation is associated with active transcription and is
under the control of HATs and HDACs. Niki et al. first described the
anti-fibrotic effects of HDAC inhibitors showing that trichostatin A
(TSA) treatment of culturedHSC suppressed fibrogenic gene expression
and proliferation [55]. HDACs are elevated in chronic liver disease and
HDAC inhibitors have been shown to suppress HSC activation and pro-
liferation [55,56] leading to a suppression offibrosis in numerous exper-
imental models including Schistosoma mansoni and BDL induced liver
fibrosis [57,58]. However the specificity of these inhibitors is ill-defined
and their functions are not completely understood. Therefore it is im-
portant to further study the activities and targets of currently available
inhibitors and to generate more specific HDAC inhibitors for future in-
vestigation. Our laboratory described a role for HDAC1 as an epigenetic
co-repressor of NF-κB p50:p50 mediated dampening of inflammatory
andfibrogenic gene transcription inHSC [59].More recentlywe showed
that aged mice lacking p50 succumb to spontaneous fibrosis [60].
Hence, HDACs may have fibrosis promoting and inhibiting activities
which complicates their therapeutic targeting. As previously discussed,
environmental factors can induce the activity of histone modifiers. In
2005 Kim et al. demonstrated that ethanol exposure caused a dose
and time dependent increase in acetylation of histone H3 at Lys9 in
rat HSCs [61]. The H3K4 methyltransferase MLL1 is up-regulated in
HSC transdifferentiated in the presence of ethanol, this leading to wide-
spread changes in chromatin structure and altered expression of
profibrogenic genes including elastin [62]. Targeting individual histone
methyltransferases may be attractive and these enzymes are currently
the subject of intense drug discovery [14]. However, they tend to be
ubiquitous enzymes playing important functions in multiple cell types
including hepatocytes. We and others have recently provided early
proof-of-concept that selective in vivo delivery of histone methyltrans-
ferase inhibitors to HSC can potently inhibit liver fibrosis [43,54,63]. By
encapsulating 3-deazaneplanocin A (dZNep), a broad specificity histone
methyltransferase inhibitor, into liposomes coatedwith theHSC-specif-
ic single chain antibody C1–3, we were able to suppress HSC
transdifferentiation and progressive fibrosis in the context of continu-
ous CCl4-induced liver damage [64]. The BET histone readers are now
emerging as potential targets for development of anti-fibrotics, as an
example Ding et al. described BRD4 binding at the enhancers of
fibrogenic genes and presented data suggesting that the BRD4 inhibitor
JQ1 may be able to suppress or even reverse fibrosis in vivo [65].
3.3. Regulatory RNAs
A large number of miRNAs have been described that both promote
(e.g. miR-145, miR-200a) and suppress (e.g. miR-338-3p, miR-378a-
3p) HSC transdifferentiation [66–69]. The most extensively
characterised miRNAs in liver fibrosis are the miR-29 family [70].
Roderburg and colleagues discovered that all three members of the
miR-29 family were downregulated in the liver of mice after CCl4 expo-
sure or BDL, this observation being confirmed in human liver with ad-
vanced fibrosis [71]. Down-regulation of miR-29 in murine HSCs was
mediated by TGF-β and experimental overexpression of miR-29b re-
sulted in down-regulation of collagen expression [71]. More recently
miR-29a overexpression was shown to ameliorate cholestatic liverfibrosis after bile duct ligation by decreasing HSC fibrotic gene expres-
sion, proliferation andmigration [72]. In a subsequent study it was pro-
posed that miR-29a mode of action was through the suppression of
methyltransferases including DNMT1, DNMT3B and SET domain con-
taining 1A (SET1A) leading to a DNA hypomethylation state that de-
creases fibrogenic activities in HSC [73]. Of note is that miR-29
mimicry (developed by miRagen Therapeutics) has been proposed as
a therapy for pulmonary fibrosis [74]. A recent study by Zhou et al. has
identified N3600 lncRNAs in human HSC, many of which are regulated
by TGF-β and enriched in extracellular matrix (ECM) networks. Sig-
nificantly the authors go on to show that 16 lncRNAs that form a net-
work with ECM proteins in adult HSC were also significantly
enriched in fibrotic human liver providing in vivo relevance [75]. Ho-
meobox transcript antisense RNA (HOTAIR), a long intergenic non-
coding RNA, is upregulated in HSCs in vivo and in vitro during liver fi-
brosis, with HOTAIR knockdown suppressing HSC activation. The au-
thors further demonstrated that HOTAIR downregulates miR-29b
expression, attenuating its control on epigenetic regulation, leading
to enhanced phosphatase and tensin homolog (PTEN) methylation,
which contributes to the progression of liver fibrosis [76]. It is there-
fore highly probable that lncRNAs are playing an important role in
HSC activation and function in the context of liver disease, however
we are a considerable way from lncRNAs being exploited therapeuti-
cally or as fibrosis biomarkers.
4. Epigenetic drivers of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the 3rd leading cause of can-
cer deaths worldwide and treatment options are severely limited.
There is a clear need for the identification of the molecular drivers
of HCC if progress is to be made in developing new medicines.
Deep sequencing studies have been instrumental in identifying
gene mutations and potential disease drivers in HCC. Alongside
these genetic approaches is an increasing awareness of the role of
epigenetic regulators in HCC which have strong potential for drug
and biomarker design.
4.1. DNA methylation
DNAmethylation changes are common in human cancers and it was
therefore unsurprising that 3700 hypomethylated promoters were
identified in HCC tumour samples [77]. Further analysis revealed the af-
fected genes to be predominantly involved in cell proliferation, adhe-
sion, cell signaling, mobility and invasion (i.e. ARF1, CASD1, MAP3K4,
MMP14 and RALA) [78]. In contrast to these hypomethylated genes, a
number of tumour suppressor genes (TSG) have been found to be
hypermethylated in early HCC including HIC1, GSTP1, SOCS1, RASSF1,
CDKN2A, APC, RUNX3 and PRDM2 [79,80]. However, the caveat with
all DNA methylation studies is that promoter methylation should be
correlated with gene expression profiling to confirm that the modifica-
tion is associated with a dramatic change in transcription. A recent
study correlated 3 genome wide DNA methylation data sets (approx.
800 samples consisting of 646 tumour and 134 non tumour samples)
with corresponding gene expression data sets. Results confirmed
that hypermethylated patterns were highly consistent, with 84
sites from 61 promoters being hypermethylated in all 3 data sets
including the previously reported CDKL2, TBX15 and NKX6-2
promoters. These data were used to subsequently classify tumour v
non-tumour samples based on 10 selected probes. Integrative
analysis identified 222 candidate epidrivers including the high
confidence candidates SFN, SPP1 and TKT all significantly associated
with patient overall survival [81].
There is vast potential for alterations in DNA methylation in HCC to
be exploited for future drug and biomarker development. The de-meth-
ylating agent decitabine has been used to validate the expression of
hypermethylated TSG in primary HCC and also re-expression of genes
128 C.L. Wilson et al. / Advanced Drug Delivery Reviews 121 (2017) 124–132in HCC cell lines. 13 candidate TSG were identified in this study includ-
ing DGK1, LDHB, NEFH, SMPD3, ACTL6B and PRPH. Functional charac-
terisation of 2 candidates, SMPD3 and NEFH, revealed that
overexpression leads to inhibition of cell proliferation, whereas by con-
trast knockdown increased tumour formation in vivo. Reduced SMPD3
expression was associated with early HCC recurrence following resec-
tion [82]. SMPD3 encodes an enzyme responsible for the production of
ceramide in response to cellular stress [83]. It was recently reported
that ceramide is markedly reduced in HCC tissue, hence epigenetic
unmasking of SMPD3 may be of therapeutic value [84]. Guadecitabine,
a dinucleotide anti-metabolite of decitabine, inhibits DNMTs and has
been recently shown to suppress tumour growth in vivo in a xenograft
HCC HepG2 model. CDKN2A, DLEC1 and RUNX3 promoters were all
confirmed to be demethylated in HCC lines following Guadecitabine
treatment and correlated with inhibition of cell growth. Importantly,
in contrast to decitabine, Guadecitabinewas able to overcome the inhib-
itory effects on cell growth by macroH2A1 (variant of histone H2A),
highlighting Guadecitabine as a potential HCC therapeutic, particularly
in advanced disease [85]. There is an urgent need for improvedminimal
invasive biomarkers for HCC, with measurement of serum alpha-feto-
protein (AFP) currently being the most commonly used marker for de-
tection of HCC suffering from low sensitivity and specificity. DNA
methylation can be readily detected and quantified in cell free circulat-
ing DNA and appears to reliably inform its tissue-of-origin [86]. Data are
now beginning to emerge that suggest that detection of alterations in
methylation in circulating cell free DNA in HCC patient plasma may
offer a more sensitive biomarker platform [87].
4.2. Histone modifications
Histone modifying enzymes offer much promise for HCC therapy
since they are tractable targets for the design of small molecule inhibi-
tors. The H3K27 methylase EZH2 is up-regulated in HCC tissue and is
associated with cancer progression, invasion and proliferation [88].
Animal studies have shown intratumoral knockdown of EZH2 pro-
motes tumour regression, this observation being confirmed in HCC
cell lines which lose their tumour initiating properties in the absence
of EZH2 [89]. Mechanisms by which EZH2 promotes HCC are begin-
ning to be revealed. Gao and colleagues have described a network
of EZH2-regulated genes including CDKN2A, FOXO3, E2F1 and
NOTCH2 that are silenced by EZH2 in HCC [90]. EZH2 silences multi-
ple miRs identified as tumour suppressors [89]. Liu and colleagues
have described how EZH2 represses the expression of miR-622
which is an important negative regulator of the chemokine receptor
CXCR4 that is implicated in multiple steps of cancer development
[91]. Loss of miR-622 was associated with elevated CXCR4 expres-
sion and poor HCC prognosis. EZH2 can also repress the expression
of antagonists of the Wnt pathway thereby promoting β-catenin-de-
pendent carcinogenesis. DZNEP is a potential therapy targeting
polycomb proteins including EZH2. However, more specific EZH2 in-
hibitors including EPZ005687 and EPZ011989 are now available and
have proved very successful at killing lymphoma cells, these new
drugs may show therapeutic promise in EZH2 high HCC patients
[92,93]. As EZH2 is a good potential biomarker for HCC progression
this may also enable easier monitoring and patient selection for
anti-EZH2 therapy (Fig. 1). PR-SET7/SETD8 is the sole H4K20 meth-
yltransferase and is a critical regulator of DNA repair and genome in-
tegrity [94,95]. Nikolaou et al. reported that deletion of PR-SET7/
SETD8 in mice results in spontaneous hepatocyte cell death, inflam-
mation, fibrosis and cancer [96]. As PR-SET7/SETD8 is reported to be
dysregulated in human HCC this may be a very relevant observation
[97]. Recurrence rates for HCC are higher in patients with elevated
expression of the H3K9methyltransferase SUV39H1 and knockdown
of this epigenetic writer impairs HCC cell growth [98]. Recruitment
of HDACs to gene promoters results in loss of histone acetylation,
compaction of chromatin and repression of transcription, a typicalexample is the p21 TSG which is transcriptionally repressed by mul-
tiple HDACs [99]. In addition, HDACs can repress transcription by re-
moving acetyl modifications from many cancer-associated
transcription factors including p53 and NF-κB [100]. Small molecule
HDAC inhibitors have potent anticancer properties and several in-
cluding vorinostat, romidepsin and belinostat are approved for im-
munological cancers [101]. In HCC, HDACs are able to promote
silencing of TSGs such as CDHL1 and enhance cancer cell survival
both in vitro and in vivo [102]. HDAC8 is upregulated in NAFLD-asso-
ciated HCC and was reported to physically associate with EZH2 to
bring about repression of Wnt antagonists and stimulate β-catenin
to promote hepatocellular growth [103]. The NAD+-dependent
HDAC Sirtuin 1 which regulates lipid, glucose and bile acid metabo-
lism is over-expressed in HCC and promotes liver cancer at least in
part via stimulating deactylation of the FXR and in turn dysregula-
tion of bile acid homeostatis [104]. This latter study cautions against
the use of sirtuin activating drugs. Clinical data to support the tu-
mour-promoting role of HDACs include the overexpression of
HDAC3 in 30–50% of HCC cases, particularly in HBV related HCC
[105]. Additionally, overexpression of HDAC3 is associated with ad-
vanced tumour stage and early recurrence post-surgery [106].
HDAC1 overexpression is associated with high cancer cell invasion
into the portal vein, poorer histological differentiation and more ad-
vanced tumour node metastasis as well as poor prognosis post resec-
tion [107]. Several inhibitors can efficiently inhibit HDAC activity in
HCC cells including panobinostat, valproate and ITF2357 [102,108].
Phase II trials with the HDAC inhibitor Belinostat in 42 patients
with advanced unresectable HCC has demonstrated efficient tumour
stabilization and is well tolerated [109]. However, progression free
survival of 2.6 months and overall survival of 6.6 months does not
improve on current therapy with Sorafenib [109]. Other HDAC inhib-
itors including abexinostat, resminostat, givinostat, panobinostat,
pracinostat, vorinostat and CUDC-101 have shown encouraging
anti-cancer properties at pre-clinical and clinical trials [110]. How-
ever, currently no HDAC inhibitors have shown any improvement
on current sorafenib therapy for HCC.
4.3. Regulatory RNAs
Previous and emerging studies in HCC are now beginning to incor-
porate ncRNAs into our molecular understanding of HCC pathogenesis
and progression [111]. The dysregulation of miRNA in cancer has been
extensively reviewed [112]. Due to the stability of these small RNAs, se-
quencing from laser capture material, paraffin embedded tissue,
exosomes and circulating serum is relatively robust. Hence, this has
led to a wealth of RNA-seq data on dysregulated miRNA expression in
tumour v non-tumour tissue in HCC [113]. miRNA fromblood and tissue
have been identified as prognostic indicators of HCC and used as bio-
markers for early detection [113]. Viral proteins are potent modulators
of variousmiRNA for exampleHbXwhich can downregulate the expres-
sion of miR-152 a known repressor of DMNT1, causing global hyperme-
thylation including that of TSG promoters [114]. Recently, RNA
sequencing from 23 liver tissues identified 5525 lncRNA, of which 57
were differentially expressed between tumour and adjacent non-tu-
mour tissue and were co-expressed with genes involved in cell cycle
control, TGFβ signaling and liver metabolism [115]. We have highlight-
ed just a few lncRNA dysregulated in HCC (Table 1) however, new
lncRNA are emerging every year including viral-human hybrid lncRNA
such as HBx-(human) LINE1 linked to carcinoma progression [116].
As the complexity of these molecular interactions unravel, we can
begin to appreciate that in most scenarios these modulators likely
work together as a network of epigenetic regulators. This highlighted
by a study demonstrating how HULC and MALAT1 combine in complex
with TRF2 to significantly increase telomerase activity and microsatel-
lite instability in liver cancer stemcells [117]. lncRNA can also act asmo-
lecular sponges inhibiting the function of tumour suppressor miRNA
Table 1
Dysregulated lncRNA in HCC.
Name Biomarker Function
HOTAIR
(HOX transcript antisense
intergenic RNA)
Upregulated in HCC and predictive of recurrence in transplant
patients [120].
siRNA knockdown in HCC cell lines sensitizes to TNFα induced
apoptosis, inhibits cell growth, induces cell cycle arrest and increases
therapeutic sensitivity [120].
Recruits EZH2 to negatively regulate miR-218 expression
subsequently resulting in the increased expression of the oncogene
BMI-1 and inactivation of the tumour-suppressors p14ARF and
P16Ink4a [121].
Inhibits the expression and phosphorylation of the methyltransferase
SETD2 resulting in the reduction of H3K36me3 and subsequent
formation of H3K36me3–hMSH2-hMSH6-SKP2 complexes, reduced
DNA mismatch repair and the potential for microsatellite instability
and abnormal expression of cell cycle related genes [122].
The viral protein HbX utilizes HOTAIR as a scaffold to induce
proteasomal degradation of repressive chromatin regulators SUZ12
and ZNF198 leading to increased expression of cancer stem cell genes
including EpCAM [123].
MALAT1
(Metastasis-associated lung
adenocarcinoma transcript 1)
Increased levels in 9 cancer cell lines and 112 HCC cases. High MALAT
expression was significantly correlated with the increased risk of HCC
recurrence post-transplant. Multivariate analysis demonstrates that
MALAT1 is an independent prognostic factor for predicting HCC
recurrence (hazard ratio, 3.280, P = 0.003) [124].
Inhibition in HEPG2 reduced viability, motility, invasiveness and
increased sensitivity to apoptosis [124].
HULC
(Highly up-regulated in liver
cancer)
Expressed in normal hepatocytes and significantly increased in liver
cancer (33 fold) [125].
A potential modulator of HBV- mediated hepatocarcinogenesis. HULC
expression is up-regulated by HbX and shown to suppress the TSG
p18 in HCC cell lines resulting in increased proliferation [126].
Promotes lipogenesis and proliferation in hepatoma cells. Shown to
suppress miR-9 preventing its repression of PPARα and thereby
promoting activation of acyl-CoA synthetase (ACSL1). The relevance
of this effect was emphasised by the observation that cholesterol
activated retinoid x receptor alpha (RXRA) further increased HULC
levels [127].
Upregulates expression of the clock circadian regulator (CLOCK)
resulting in increased proliferation of hepatoma cells both in vitro and
in vivo [128].
HULC via SPHK1 plays a role in promoting angiogenesis by
sequestering miR-107 and releasing its inhibition on E2F1 [129].
HEIH
(Hepatocellular Carcinoma
Up-Regulated EZH2-Associated
Long Non-Coding RNA)
Increased HEIH expression in HBV-related HCC was significantly
associated with HCC recurrence and is an independent prognostic
factor for survival [130].
Knockdown of HEIH in HCC cells results in loss of repression of EZH2
target genes p16, p27, p21 resulting in G0/G1 arrest and reduced cell
proliferation. The proliferative effects of HEIH are further supported
by the observation that in vivo HEIH knockdown reduces xenograft
growth [130].
H19 H19 is part of a conserved gene cluster containing the paternally
expressed imprinted Igf2 gene [131]. Expression of both H19 and Igf2
are up-regulated in HBV-related HCC [128] and an imbalance
between the proteins is associated with HCC progression [132].
Functionally, H19 promotes EZH2-mediated repression of E-cadherin,
inhibitors of the WNT signaling pathway and enhances invasion and
metastasis of HCC cell lines [133]. H19 reportedly plays a role in
resistance to doxorubicin by promoter demethylation of MDR1 and
subsequent expression of its protein P glycoprotein in HCC cell lines.
Thus, suggesting that combination H19 targeting with
chemotherapeutics may prove successful in cancer therapy [134].
129C.L. Wilson et al. / Advanced Drug Delivery Reviews 121 (2017) 124–132and influencing carcinogenesis. A deeper understanding of the mecha-
nisms by which these lncRNA influence HCC initiation and progression
will significantly advance the design of improved targeting therapies.
Therapeutic targeting of ncRNA in HCC is now an imminent chal-
lenge. Emerging pre-clinical studies utilizing sophisticated drug de-
livery nanoparticles and animal proof of concept models such as
this study successfully targeting the lncRNA TUG1 show promise
for therapeutic development of antisense oligonucleotides [118].
Clinical trials with the anti-miR-122 oligonucleotide Miravirsen
have also shown promising effects in chronic HCV patients and dem-
onstrate successful reduction in miR-122 levels [119]. Additionally,
the development of MRG-201 (MIRagen Therapeutics) as a miR-
29b agonist is currently in clinical trials for safety and efficacy with
promise for liver fibrosis, if so it may also prove successful in ad-
vanced HCC (NCT02603224).
5. Summary and future prospective
The hepatic epigenome is remarkable in its capacity to adapt to
dietary, metabolic, xenobiotic and microbial challenges in order tomaintain cellular and functional homeostasis. However, when this
capacity is breached epigenetic adaptions can become problematic
and contribute to disease pathogenesis. We are now aware of how
key components of the epigenetic machinery such as DNA methyla-
tion, histone PTMs and ncRNAs alter their expression or function in
the context of fibrosis/cirrhosis and liver cancer. The next steps are
to convert this information into bespoke medicines that either pre-
vent disease-driving epigenome reprogramming or that reverse spe-
cific disease-promoting epigenetic changes. Furthermore there is
vast potential to use the appearance of liver-derived epigenetic
markers in the patient circulation for the diagnosis and prognostic
tracking of chronic liver disease using no more than a few drops of
blood, avoiding the need for biopsy or complex and expensive imag-
ing modalities.
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